{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T22:32:24Z","timestamp":1774305144297,"version":"3.50.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T00:00:00Z","timestamp":1743379200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020869","name":"AstraZeneca KK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020869","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Investigation"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.resinv.2025.03.007","type":"journal-article","created":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T17:11:50Z","timestamp":1743959510000},"page":"444-452","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Long-term, real-world effectiveness of biologics for severe uncontrolled asthma: The PROSPECT study"],"prefix":"10.1016","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8400-863X","authenticated-orcid":false,"given":"Kazuhisa","family":"Asai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9155-265X","authenticated-orcid":false,"given":"Takashi","family":"Iwanaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mai","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0214-1056","authenticated-orcid":false,"given":"Takehiro","family":"Hirai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadataka","family":"Yabuta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoyuki","family":"Makita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Tohda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.resinv.2025.03.007_bib1","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2025.03.007_bib2","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1056\/NEJM199810223391703","article-title":"A 15-year follow-up study of ventilatory function in adults with asthma","volume":"339","author":"Lange","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2025.03.007_bib3","doi-asserted-by":"crossref","unstructured":"Matsunaga K, Hirano T, Oka A, Tanaka A, Kanai K, Kikuchi T, et al. Progression of irreversible airflow limitation in asthma: correlation with severe exacerbations. J Allergy Clin Immunol Pract 2015;3:759-764.e1. https:\/\/doi.org\/10.1016\/j.jaip.2015.05.005.","DOI":"10.1016\/j.jaip.2015.05.005"},{"key":"10.1016\/j.resinv.2025.03.007_bib4","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b2(2)-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.resinv.2025.03.007_bib5","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2025.03.007_bib6","doi-asserted-by":"crossref","first-page":"573","DOI":"10.7326\/0003-4819-154-9-201105030-00002","article-title":"Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial","volume":"154","author":"Hanania","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.resinv.2025.03.007_bib7","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2025.03.007_bib8","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1398-9995.2004.00772.x","article-title":"Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): innovate","volume":"60","author":"Humbert","year":"2005","journal-title":"Allergy"},{"key":"10.1016\/j.resinv.2025.03.007_bib9","doi-asserted-by":"crossref","unstructured":"Casale TB, Luskin AT, Busse W, Zeiger RS, Trzaskoma B, Yang M, et al. Omalizumab effectiveness by biomarker status in patients with asthma: evidence From PROSPERO, a prospective real-world study. J Allergy Clin Immunol Pract 2019;7:156-64.e1. https:\/\/doi.org\/10.1016\/j.jaip.2018.04.043.","DOI":"10.1016\/j.jaip.2018.04.043"},{"key":"10.1016\/j.resinv.2025.03.007_bib10","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1016\/j.jaip.2023.05.044","article-title":"Impact of initiating biologics in patients with severe asthma on long-term oral corticosteroids or frequent rescue steroids (GLITTER): data from the International Severe Asthma Registry","volume":"11","author":"Chen","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.resinv.2025.03.007_bib12","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2147\/JAA.S410292","article-title":"Characterization of severe uncontrolled asthma in Japan: analysis of baseline data from the PROSPECT study","volume":"16","author":"Koya","year":"2023","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.resinv.2025.03.007_bib13","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1034\/j.1399-3003.1999.14d29.x","article-title":"Development and validation of a questionnaire to measure asthma control","volume":"14","author":"Juniper","year":"1999","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2025.03.007_bib14","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.rmed.2004.10.008","article-title":"Measurement properties and interpretation of three shortened versions of the asthma control questionnaire","volume":"99","author":"Juniper","year":"2005","journal-title":"Respir Med"},{"key":"10.1016\/j.resinv.2025.03.007_bib15","doi-asserted-by":"crossref","unstructured":"Perez-de-Llano L, Scelo G, Canonica GW, Chen W, Henley W, Larenas-Linnemann D, et al. Impact of pre-biologic impairment on meeting domain-specific biologic responder definitions in patients with severe asthma. Ann Allergy Asthma Immunol 2024;132:610-22.e7. https:\/\/doi.org\/10.1016\/j.anai.2023.12.023.","DOI":"10.1016\/j.anai.2023.12.023"},{"key":"10.1016\/j.resinv.2025.03.007_bib16","doi-asserted-by":"crossref","DOI":"10.1177\/17534666231202749","article-title":"Improvement in severe asthma patients receiving biologics and factors associated with persistent insufficient control: a real-life national study","volume":"17","author":"Guilleminault","year":"2023","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.resinv.2025.03.007_bib17","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma","volume":"378","author":"Rabe","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2025.03.007_bib18","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid-sparing effect of benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2025.03.007_bib19","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2025.03.007_bib20","doi-asserted-by":"crossref","first-page":"609","DOI":"10.2147\/JAA.S311975","article-title":"Effectiveness of switching biologics for severe asthma patients in Japan: a single-center retrospective study","volume":"14","author":"Numata","year":"2021","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.resinv.2025.03.007_bib21","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2147\/JAA.S328653","article-title":"Real world biologic use and switch patterns in severe asthma: data from the International Severe Asthma Registry and the US CHRONICLE Study","volume":"15","author":"Menzies-Gow","year":"2022","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.resinv.2025.03.007_bib22","doi-asserted-by":"crossref","unstructured":"Liu MC, Bagnasco D, Matucci A, Pilette C, Price RG, Maxwell AC, et al. Mepolizumab in patients with severe asthma and comorbidities: 1-year REALITI-A analysis. J Allergy Clin Immunol Pract 2023;11:3650-61.e3. https:\/\/doi.org\/10.1016\/j.jaip.2023.07.024.","DOI":"10.1016\/j.jaip.2023.07.024"},{"key":"10.1016\/j.resinv.2025.03.007_bib23","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2147\/JAA.S432695","article-title":"Real-world safety and effectiveness of benralizumab in Japanese patients with severe asthma: a multicenter prospective observational study","volume":"17","author":"Yamaguchi","year":"2024","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.resinv.2025.03.007_bib24","doi-asserted-by":"crossref","unstructured":"Abe K, Miyawaki A, Nakamura M, Ninomiya H, Kobayashi Y. Trends in hospitalizations for asthma during the COVID-19 outbreak in Japan. J Allergy Clin Immunol Pract 2021;9:494-496.e1. https:\/\/doi.org\/10.1016\/j.jaip.2020.09.060.","DOI":"10.1016\/j.jaip.2020.09.060"}],"container-title":["Respiratory Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534525000322?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534525000322?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T12:57:25Z","timestamp":1762606645000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212534525000322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S2212534525000322"],"URL":"https:\/\/doi.org\/10.1016\/j.resinv.2025.03.007","relation":{},"ISSN":["2212-5345"],"issn-type":[{"value":"2212-5345","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term, real-world effectiveness of biologics for severe uncontrolled asthma: The PROSPECT study","name":"articletitle","label":"Article Title"},{"value":"Respiratory Investigation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.resinv.2025.03.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of The Japanese Respiratory Society.","name":"copyright","label":"Copyright"}]}}